These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11763165)

  • 1. The Hsp90 chaperone as a promising drug target.
    Piper PW
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1606-10. PubMed ID: 11763165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C; Lang SA; Stoeltzing O
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37.
    Nony P; Gaude H; Rossel M; Fournier L; Rouault JP; Billaud M
    Oncogene; 2003 Dec; 22(57):9165-75. PubMed ID: 14668798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70.
    Wang Y; Wang SY; Zhang XH; Zhao M; Hou CM; Xu YJ; Du ZY; Yu XD
    Biochem Biophys Res Commun; 2007 May; 356(4):998-1003. PubMed ID: 17397803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Hsp90 for the treatment of cancer.
    Drysdale MJ; Brough PA; Massey A; Jensen MR; Schoepfer J
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):483-95. PubMed ID: 16889231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.
    McErlean CS; Proisy N; Davis CJ; Boland NA; Sharp SY; Boxall K; Slawin AM; Workman P; Moody CJ
    Org Biomol Chem; 2007 Feb; 5(3):531-46. PubMed ID: 17252137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATPase inhibitors of heat-shock protein 90, second season.
    Janin YL
    Drug Discov Today; 2010 May; 15(9-10):342-53. PubMed ID: 20230904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat shock protein 90: a unique chemotherapeutic target.
    Cullinan SB; Whitesell L
    Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
    Sanam R; Tajne S; Gundla R; Vadivelan S; Machiraju PK; Dayam R; Narasu L; Jagarlapudi S; Neamati N
    J Mol Graph Model; 2010 Feb; 28(6):472-7. PubMed ID: 20005756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
    Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hsp90--a target for anticancer therapy].
    Růcková E; Müller P; Vojtesek B
    Klin Onkol; 2011; 24(5):329-37. PubMed ID: 22070013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsp90: a chaperone for protein folding and gene regulation.
    Zhao R; Houry WA
    Biochem Cell Biol; 2005 Dec; 83(6):703-10. PubMed ID: 16333321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity.
    Rowlands MG; Newbatt YM; Prodromou C; Pearl LH; Workman P; Aherne W
    Anal Biochem; 2004 Apr; 327(2):176-83. PubMed ID: 15051534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity to Hsp90-targeting drugs can arise with mutation to the Hsp90 chaperone, cochaperones and plasma membrane ATP binding cassette transporters of yeast.
    Piper PW; Millson SH; Mollapour M; Panaretou B; Siligardi G; Pearl LH; Prodromou C
    Eur J Biochem; 2003 Dec; 270(23):4689-95. PubMed ID: 14622256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.